To satisfy FDA and other government regulations I cannot disclose any research materials. However, please see below for specific research studies which I was the lead researcher during my time at University of Miami.
A Phase 3, Open-label, Multicenter Study of Alxn1210 in Children and Adolescents with Atypical Hemolytic- Uremic Syndrome. https://clinicaltrials.gov/ct2/show/NCT03131219
A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms with Switchover, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome. https://clinicaltrials.gov/ct2/show/NCT02592798
A Phase III, Multicenter, Double-Blind, Randomized, Placebo- Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control. https://clinicaltrials.gov/ct2/show/NCT01485614
A Randomized, Multicenter, Double-blind, Parallel, Active- Control Study of the Effects of Sparsentan, a dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis. https://clinicaltrials.gov/ct2/show/NCT03493685
Clinical Evaluation of the Prismaflex HF20 Set and Prismaflex® System 7.10 for Acute Continuous Renal Replacement Therapy (CRRT) in Children. https://clinicaltrials.gov/ct2/show/NCT02561247
Present An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules) in Pediatric Patients With Chronic Kidney Disease Stages 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis. https://clinicaltrials.gov/ct2/show/NCT02859896
A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension, and Vancomycin Oral Liquid or Capsules Taken for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea. https://clinicaltrials.gov/ct2/show/NCT02218372
Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HyQvia in Pediatric Subjects with Primary Immunodeficiency Diseases. https://clinicaltrials.gov/ct2/show/NCT03277313
ACTHAR for the Management of Treatment-resistant Nephrotic Syndrome in Children: A Pilot Study. https://clinicaltrials.gov/ct2/show/NCT03408405
An Open-label, Randomized, Active-controlled, Parallel Group, Multicenter, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Pediatric and Adolescent CKD Patients With Hypophosphatemia. https://clinicaltrials.gov/ct2/show/NCT02688764
A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (Azilsartan Medoxomil) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hypertension. https://www.clinicaltrials.gov/ct2/show/NCT02235909
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children, Ages 7 to 17 Years. https://clinicaltrials.gov/ct2/show/NCT02559817
Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered via Dialysate and IV to Pediatric Patients on Chronic Hemodialysis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153505/